Intravitreal Aflibercept 8 mg Injection in Patients With
Neovascular Age-Related Macular Degeneration: 60-Week and
96-Week Results from the Phase 3 PULSAR Trial
Efficacy and Safety of Avacincaptad Pegol in Patients With
Geographic Atrophy (GATHER2): 12-Month Results from a
Randomized, Double-Masked, Phase 3 Trial
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration (nAMD): 48-week results from the Phase 3 PULSAR trial
Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration
The Efficacy of Avacincaptad Pegol in Geographic Atrophy: GATHER1 and GATHER2 Results
Assessment of geographic atrophy progression in the phase 3 OAKS and DERBY trials
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration
‘What should I inject next?’’ Challenging treatment decisions in the multiple anti-VEGF: a review of publications exploring anti-VEGF switching for nAMD
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomized, double-masked, phase 3, non-inferiority trials
Faricimab in Neovascular Age-Related Macular Degeneration: Primary Results From the Phase 3 TENAYA and LUCERNE Trials
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Efficacy and Safety of Intravitreal Aflibercept Using a Treat-And-Extend Regimen for Neovascular Age-Related Macular Degeneration The ARIES Study: A Randomized Clinical Trial
Diagnostic Accuracy of Monitoring Tests of Fellow Eyes in Patients with Unilateral Neovascular Age-Related Macular Degeneration Early Detection of Neovascular Age-Related Macular Degeneration Study (EDNA)
Efficacy and Safety of Intravitreal Pegcetacoplan in GA: Results From the Phase 3 DERBY and OAKS Trials
Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration (AMD): Data From an Observational Study
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration (AMD) according to LUCAS treat-and-extend protocol
Clinical classification of Age-related Macular Degeneration (AMD)
Efficacy of a treat-and-extend (T&E) regimen with ranibizumab in patients with neovascular age-related macular disease (nAMD): A randomized clinical trial
HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration (nAMD)
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP)
Outcomes of Patients With Exudative Age-Related Macular Degeneration Treated With Antivascular Endothelial Grouth Factor Therapy for Three or More Years: A review of Current Outcomes
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degenerationo Treated with Ranibizumab Using a Treat-and-Extend Regimen
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-related Macular Degeneration: 52- and 96-Week Findings From ALTAIR
Ranibizumab Treatment in Treatment-Naive Neovascular Age-related Macular Degeneration: Results From LUMINOUS, A Global Real-World Study